Actinium Pharmaceuticals, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Actinium Pharmaceuticals, Inc. has filed its 2023 annual report (10-K) detailing its corporate information and filing compliance.</b>

AI Summary

Actinium Pharmaceuticals, Inc. (ATNM) filed a Annual Report (10-K) with the SEC on March 29, 2024. Actinium Pharmaceuticals, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023. The company is incorporated in Delaware and its principal executive offices are located at 100 Park Ave., New York, NY. Its common stock, par value $0.001, is traded on the NYSE American under the symbol ATNM. Actinium Pharmaceuticals, Inc. was formerly known as Cactus Ventures, Inc. until January 30, 2007. The company has confirmed it has filed all required reports for the preceding 12 months and has been subject to filing requirements for the past 90 days.

Why It Matters

For investors and stakeholders tracking Actinium Pharmaceuticals, Inc., this filing contains several important signals. This filing provides a comprehensive overview of Actinium Pharmaceuticals' corporate structure, financial reporting history, and stock exchange listing, which is crucial for investors to assess the company's stability and compliance. The report confirms the company's status as a non-accelerated filer and smaller reporting company, offering insights into its size and regulatory obligations relevant to potential investors and analysts.

Risk Assessment

Risk Level: low — Actinium Pharmaceuticals, Inc. shows low risk based on this filing. The filing is a standard annual report (10-K) and does not contain specific financial performance data or forward-looking statements that would indicate immediate risk.

Analyst Insight

Review the full 10-K filing for detailed financial statements, risk factors, and management discussion to understand Actinium Pharmaceuticals' operational and financial health.

Key Numbers

• 20231231 — Fiscal Year End (The report covers the fiscal year ended December 31, 2023.)
• 20240329 — Filing Date (The Form 10-K was filed on March 29, 2024.)
• 001-36374 — Commission File Number (The SEC file number assigned to the registrant.)
• $0.001 — Par Value of Common Stock (The par value of the company's common stock.)

Key Players & Entities

• Actinium Pharmaceuticals, Inc. (company) — Filer name
• 20231231 (date) — Fiscal year end
• 20240329 (date) — Filing date
• 100 Park Ave., 23rd Floor (address) — Principal executive offices
• New York (location) — City of principal executive offices
• NY (location) — State of principal executive offices
• ATNM (ticker) — Trading symbol for common stock
• NYSE American (exchange) — Name of exchange where common stock is registered

FAQ

Industry Context

Actinium Pharmaceuticals operates within the pharmaceutical preparations industry, focusing on the development and commercialization of targeted cancer therapies.

Regulatory Implications

As a publicly traded company, Actinium Pharmaceuticals is subject to the reporting requirements of the Securities Exchange Act of 1934, including the filing of annual reports (Form 10-K).

What Investors Should Do

1. Analyze the full 10-K for detailed financial performance, including revenue, expenses, and cash flow.
2. Review the 'Risk Factors' section for potential challenges and uncertainties facing the company.
3. Examine the 'Management's Discussion and Analysis of Financial Condition and Results of Operations' for insights into business strategy and outlook.

Year-Over-Year Comparison

This filing is the annual report for the fiscal year ended December 31, 2023, and serves as a comprehensive update to the company's status and operations.

Key Financial Figures

• $0.001 — ich registered Common stock, par value $0.001 ATNM NYSE American Securities registe
• $76.7 million — At year-end 2023, we had approximately $76.7 million of cash on hand. As of March 27, 2024,
• $84.3 million — 27, 2024, our unaudited cash on hand of $84.3 million is expected to fund operations into the
• $439 — atients with r/r AML were approximately $439 thousand, with hospitalization as the l

Filing Documents

• f10k2023_actinium.htm (10-K) — 1237KB
• f10k2023ex23-1_act.htm (EX-23.1) — 3KB
• f10k2023ex31-1_act.htm (EX-31.1) — 11KB
• f10k2023ex31-2_act.htm (EX-31.2) — 10KB
• f10k2023ex32-1_act.htm (EX-32.1) — 4KB
• f10k2023ex32-2_act.htm (EX-32.2) — 4KB
• f10k2023ex97-1_act.htm (EX-97.1) — 31KB
• image_001.jpg (GRAPHIC) — 684KB
• image_002.jpg (GRAPHIC) — 336KB
• image_003.jpg (GRAPHIC) — 521KB
• image_004.jpg (GRAPHIC) — 204KB
• image_005.jpg (GRAPHIC) — 684KB
• image_006.jpg (GRAPHIC) — 333KB
• image_007.jpg (GRAPHIC) — 449KB
• image_008.jpg (GRAPHIC) — 360KB
• image_009.jpg (GRAPHIC) — 206KB
• image_010.jpg (GRAPHIC) — 121KB
• image_011.jpg (GRAPHIC) — 243KB
• image_012.jpg (GRAPHIC) — 267KB
• image_013.jpg (GRAPHIC) — 448KB
• image_014.jpg (GRAPHIC) — 552KB
• 0001213900-24-028038.txt (&nbsp;) — 17826KB
• atnm-20231231.xsd (EX-101.SCH) — 47KB
• atnm-20231231_cal.xml (EX-101.CAL) — 37KB
• atnm-20231231_def.xml (EX-101.DEF) — 214KB
• atnm-20231231_lab.xml (EX-101.LAB) — 417KB
• atnm-20231231_pre.xml (EX-101.PRE) — 214KB
• f10k2023_actinium_htm.xml (XML) — 393KB

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 30 Item 1B. Unresolved Staff Comments 61 Item 1C. Cybersecurity 61 Item 2.

Properties

Properties 61 Item 3.

Legal Proceedings

Legal Proceedings 61 Item 4. Mine Safety Disclosures 61 Item 5. Market for Registrant's Common Equity, Related Stockholders Matters, and Issuer Purchases of Equity Securities 62 Item 6. Reserved 62 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 63 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 69 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data F-1 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 70 Item 9A.

Controls and Procedures

Controls and Procedures 70 Item 9B. Other Information 70 Item 9C Disclosure Regarding Foreign Jurisdictions That Prevent Inspections 70 Item 10. Directors, Executive Officers and Corporate Governance 71 Item 11.

Executive Compensation

Executive Compensation 83 Item 12.

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 87 Item 13. Certain Relationships and Related Transactions, and Director Independence 89 Item 14. Principal Accountant Fees and Services 89 Item 15. Exhibits, Financial Statement Schedules 90 Signature Page 94 i CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K (this "Report") contains forward-looking statements that involve risks and uncertainties, principally in the sections entitled "Description of Business," "Risk Factors," and "Management's Discussion and Analysis of Financial Condition and Results of Operations." All statements other than statements of historical fact contained in this Report, including statements regarding future events, our future financial performance, business strategy and plans and objectives of management for future operations, are forward-looking statements. We have attempted to identify forward-looking statements by terminology including "anticipates," "believes," "can," "continue," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "should," or "will" or the negative of these terms or other comparable terminology. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks outlined under "Risk Factors" or elsewhere in this Report, which may cause our or our industry's actual results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time and it is not possible for us to predict all risk factors, nor can we address the impact of all factors on our business or the extent to which any factor, or combination of factors

BUSINESS

ITEM 1. BUSINESS. Description of Our Business Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") develops targeted radiotherapies intended to meaningfully improve survival for patients with relapsed or refractory cancer who have failed existing therapies. Our vision is to build a specialty, hospital-focused, radiotherapeutics company that develops and markets medicines for patients who are treated primarily in large quaternary care hospitals and their catchment areas. We are deploying our technology platform, which we believe to be industry-leading, and intellectual property, with over 230 issued and pending patents worldwide, to develop ARCs, or Antibody Radiation Conjugates, and next-generation radiotherapies against validated cancer targets. Pipeline Highlights We intend to leverage the clinical data of our lead product candidates, Iomab-B and Actimab-A, to potentially improve outcomes in patients with relapsed or refractory acute myeloid leukemia ("r/r AML") by launching two radiotherapy drugs over the next several years to address the significant unmet need for better outcomes from treatment with therapeutics or from undergoing a bone marrow transplant ("BMT"). We also intend to further advance Iomab-B beyond acute myeloid leukemia ("AML"), based on promising data as a disease control and conditioning agent for various other blood cancers. Based on early clinical trial results, we are also working on a next-generation conditioning program, Iomab-ACT, for rapidly growing cell and gene therapies. Our Next Generation ARC Pipeline AML is an aggressive, heterogeneous disease that is difficult to treat. Over 50% of AML patients develop relapsed or refractory disease within one year of being afflicted and have an extremely poor prognosis and dismal survival. Currently, a BMT is regarded as being able to provide the best treatment outcome and is the only curative regimen available for AML patients, however, access is limited to less than 20% of all

View Full Filing

View this 10-K filing on SEC EDGAR